AcelRx Pharmaceuticals (ACRX) Expected to Post Earnings of -$0.24 Per Share

Analysts expect AcelRx Pharmaceuticals (NASDAQ:ACRX) to announce earnings per share (EPS) of ($0.24) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with estimates ranging from ($0.24) to ($0.23). AcelRx Pharmaceuticals posted earnings of ($0.34) per share in the same quarter last year, which would suggest a positive year over year growth rate of 29.4%. The business is scheduled to issue its next quarterly earnings report on Monday, May 14th.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year earnings of ($0.98) per share for the current fiscal year, with EPS estimates ranging from ($1.01) to ($0.95). For the next financial year, analysts forecast that the business will post earnings of ($0.84) per share, with EPS estimates ranging from ($0.97) to ($0.70). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover AcelRx Pharmaceuticals.

How to Become a New Pot Stock Millionaire

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). The business had revenue of $0.74 million for the quarter, compared to analyst estimates of $2.90 million.

Separately, Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. AcelRx Pharmaceuticals has a consensus rating of “Hold” and an average target price of $4.92.

A hedge fund recently bought a new stake in AcelRx Pharmaceuticals stock. Virtu Financial LLC bought a new stake in AcelRx Pharmaceuticals (NASDAQ:ACRX) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 59,184 shares of the specialty pharmaceutical company’s stock, valued at approximately $120,000. Virtu Financial LLC owned 0.12% of AcelRx Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 9.20% of the company’s stock.

NASDAQ ACRX traded up $0.03 on Friday, hitting $2.20. 214,343 shares of the company’s stock traded hands, compared to its average volume of 541,584. The company has a current ratio of 4.64, a quick ratio of 4.57 and a debt-to-equity ratio of -0.31. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The stock has a market cap of $111.98, a price-to-earnings ratio of -2.00 and a beta of 2.42.

TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/acelrx-pharmaceuticals-acrx-expected-to-post-earnings-of-0-24-per-share.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply